Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI... Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 25 | 25 | 25 | 200 | 25 | CS |
| 4 | 0.566 | 2.31644429893 | 24.434 | 25 | 23.813931 | 1554 | 23.88117072 | CS |
| 12 | -5 | -16.6666666667 | 30 | 30 | 23.813931 | 1096 | 24.72830433 | CS |
| 26 | -7 | -21.875 | 32 | 35 | 23.813931 | 717 | 26.67181145 | CS |
| 52 | -4 | -13.7931034483 | 29 | 35.83 | 23.813931 | 902 | 27.85538015 | CS |
| 156 | -43.9 | -63.7155297533 | 68.9 | 70.4 | 22.51 | 1454 | 37.89213625 | CS |
| 260 | -68.97 | -73.3957646057 | 93.97 | 95.9892 | 22.51 | 2171 | 53.1514382 | CS |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。